Pro Medicus Ltd (ASX: PME) Share Price and News





  (20 mins delayed)

52 Week Range


1 Year Return


Pro Medicus Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $13.70 billion
P/E Ratio 196.80
Dividend Yield 0.27%
Shares Outstanding 104.42 million
Earnings per share 0.667
Dividend per share 0.36
Year To Date Return 37.07%
Earnings Yield 0.51%
Franking 100%
Share Price

Day Change

52 Week Range


Yesterday's Close

Today's Open

Days Range



Avg. Volume (1 month)


as at 24 Feb 3:44pm

  • Pro Medicus Ltd (ASX: PME)
    Latest News

    three businessmen high five each other outside an office building with graphic images of graphs and metrics superimposed on the shot.
    Growth Shares

    2 excellent ASX shares to buy and hold for a decade

    Looking for buy and hold investments? Analysts think these are top picks.

    Read more »

    A happy couple drinking red wine in a vineyard as the Treasury Wine share price rises today
    Share Gainers

    Here are the top 10 ASX 200 shares today

    ASX investors were back to buying this Wednesday.

    Read more »

    A female ASX investor looks through a magnifying glass that enlarges her eye and holds her hand to her face with her mouth open as if looking at something of great interest or surprise.
    Broker Notes

    Top brokers name 3 ASX shares to buy next week

    Brokers gave buy ratings to these ASX shares last week. Why are they bullish?

    Read more »

    Three hikers lift their arms in jubilation as they reach a rocky peak overlooking a sensational view of water and mountains with a blue sky surrounding them.
    Share Market News

    Guess which 3 ASX 200 shares are leading the charge higher this week

    Investors piled into these three ASX 200 shares over the week. But why?

    Read more »

    A group of people in a corporate setting do a collective high five.
    Healthcare Shares

    Can this ASX 200 share still be a buy if it's 'one of the world's most expensive stocks'?

    Experts are choosing to look past this company's soaring valuation.

    Read more »

    Smiling man with phone in wheelchair watching stocks and trends on computer
    Share Market News

    5 things to watch on the ASX 200 on Friday

    A decent finish to the week is expected for Aussie investors.

    Read more »

    A young man sits on the floor with his back against a sofa hunched over his phone in one hand and his other hand on top of his head as though he is seeing bad news as his face looks sad and anguished.
    Share Market News

    Here are the top 10 ASX 200 shares today

    ASX investors copped yet another bruising in the markets today.

    Read more »

    A young woman holding her phone smiles broadly and looks excited, after receiving good news.
    Share Gainers

    Why Catapult, Clarity, Pro Medicus, and Qantas shares are rising today

    These shares are avoiding the market weakness on Thursday and pushing higher. But why?

    Read more »

    Investor sitting in front of multiple screens watching share prices
    Broker Notes

    Top brokers name 3 ASX shares to buy today

    Here's what brokers are recommending as buys this week.

    Read more »

    A man and woman in an office look at a laptop and discuss investing, budget strategies or other financial concepts
    Technology Shares

    Why you should buy this 'industry leading' ASX 200 tech stock

    Goldman Sachs thinks investors should be buying this high-quality company's shares.

    Read more »

    Business woman watching stocks and trends while thinking
    Share Market News

    5 things to watch on the ASX 200 on Wednesday

    It could be a tough session for Aussie investors today.

    Read more »

    The silhouettes of ten people holding hands with their arms raised against the sky, as the sun rises or sets in the background.
    Share Gainers

    Here are the top 10 ASX 200 shares today

    It was a drop back to reality for ASX investors this Tuesday.

    Read more »

    Frequently Asked Questions

    Yes, the company historically pays two fully franked dividends a year. 

    Pro Medicus generally pays its shareholder dividends in March and October.

    Pro Medicus Ltd listed on the ASX on 10 October 2000.

    Dividend Payment History Data provided by Morningstar.

    Data provided by Morningstar.
    Ex-Date Amount Franking Type Payable
    29 Feb 2024 $0.1800 100.00% Interim 22 Mar 2024
    06 Sep 2023 $0.1700 100.00% Final 28 Sep 2023
    02 Mar 2023 $0.1300 100.00% Interim 24 Mar 2023
    08 Sep 2022 $0.1200 100.00% Final 30 Sep 2022
    03 Mar 2022 $0.1000 100.00% Interim 25 Mar 2022
    09 Sep 2021 $0.0800 100.00% Final 01 Oct 2021
    04 Mar 2021 $0.0700 100.00% Interim 19 Mar 2021
    10 Sep 2020 $0.0600 100.00% Final 02 Oct 2020
    05 Mar 2020 $0.0600 100.00% Interim 20 Mar 2020
    12 Sep 2019 $0.0450 100.00% Final 04 Oct 2019
    12 Mar 2019 $0.0250 100.00% Special Cash 17 May 2019
    07 Mar 2019 $0.0350 100.00% Interim 22 Mar 2019
    06 Sep 2018 $0.0350 100.00% Final 27 Sep 2018
    08 Mar 2018 $0.0250 100.00% Interim 23 Mar 2018
    07 Sep 2017 $0.0000 100.00% Final 28 Sep 2017
    08 Sep 2016 $0.0150 0.00% Final 29 Sep 2016
    10 Mar 2016 $0.0150 0.00% Interim 24 Mar 2016
    15 Mar 2006 $0.0050 100.00% Special 05 Apr 2006
    15 Mar 2006 $0.0200 100.00% Interim 05 Apr 2006
    14 Sep 2005 $0.0050 100.00% Special Cash 04 Oct 2005
    14 Sep 2005 $0.0275 100.00% Final 04 Oct 2005
    16 Mar 2004 $0.0125 100.00% Interim 05 Apr 2004

    PME ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size

    About Pro Medicus Ltd

    Pro Medicus Ltd (ASX: PME) is a provider of medical imaging technology globally. The company is recognised as a leading supplier of radiology information systems (RIS), picture archiving and communication systems (PACS), and advanced visualisation solutions for medical practices and hospitals.

    Pro Medicus's RIS technology products also include medical accounting, clinical reporting, appointments/scheduling, and marketing/management applications. The company's services to the imaging sector cover workflow mapping and optimisation, network design and implementation, hardware sourcing and configuration, and staff and management training.

    Pro Medicus has offices in Australia, Germany, and the US with its products adopted by many top-tier hospitals and health facilities, particularly in the US market.

    PME Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    14 Jun 2024 $131.17 $-2.05 -1.54% 220,715 $133.00 $133.23 $130.72
    13 Jun 2024 $133.22 $3.12 2.40% 323,360 $131.75 $133.22 $131.38
    12 Jun 2024 $130.10 $2.04 1.59% 368,168 $128.02 $130.32 $128.01
    11 Jun 2024 $128.06 $2.19 1.74% 376,619 $125.03 $128.70 $124.19
    07 Jun 2024 $125.87 $3.34 2.73% 261,953 $123.57 $125.92 $123.17
    06 Jun 2024 $122.53 $-0.39 -0.32% 387,558 $124.75 $126.70 $120.67
    05 Jun 2024 $122.92 $5.44 4.63% 407,333 $119.83 $122.92 $118.79
    04 Jun 2024 $117.48 $-3.75 -3.09% 196,164 $121.56 $122.51 $117.36
    03 Jun 2024 $121.23 $1.11 0.92% 303,179 $123.50 $124.24 $119.14
    31 May 2024 $120.12 $0.05 0.04% 5,865,815 $124.46 $124.73 $120.12
    30 May 2024 $120.07 $4.18 3.61% 348,537 $114.11 $120.07 $114.11
    29 May 2024 $115.89 $1.58 1.38% 325,295 $114.38 $115.89 $114.21
    28 May 2024 $114.31 $1.07 0.94% 269,391 $119.50 $119.50 $114.10
    27 May 2024 $113.24 $-2.46 -2.13% 156,300 $116.50 $117.48 $112.73
    24 May 2024 $115.70 $0.15 0.13% 128,713 $114.56 $116.02 $113.79
    23 May 2024 $115.55 $0.73 0.64% 227,897 $114.23 $118.69 $114.23
    22 May 2024 $114.82 $2.16 1.92% 238,090 $112.76 $114.95 $112.72
    21 May 2024 $112.66 $-3.35 -2.89% 375,566 $115.91 $117.26 $112.19
    20 May 2024 $116.01 $-0.89 -0.76% 200,525 $117.50 $119.09 $116.01
    17 May 2024 $116.90 $-2.86 -2.39% 231,370 $118.50 $119.38 $116.90

    Director Transactions Data provided by Morningstar.

    Data provided by Morningstar.
    Date Director Type Amount Value Notes
    21 Feb 2024 Alice Williams Buy 850 $74,681
    On-market trade.
    16 Feb 2024 Alice Williams Buy 810 $72,875
    On-market trade.
    27 Nov 2023 Alice Williams Buy 250 $22,510
    On-market trade.
    21 Nov 2023 Anthony Hall Sell 1,000,000 $88,020,000
    On-market trade.
    21 Nov 2023 Sam Hupert Sell 1,000,000 $88,020,000
    On-market trade.
    25 Aug 2023 Anthony Hall Transfer 70,000 $5,030,200
    Off-market transfer. non-cash, Estimated value

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Dr Sam Aaron Hupert Chief Executive OfficerManaging Director Oct 2007
    Dr Hupert served as CEO from the time he co-founded the company until October 2007 at which time he stepped down to become an executive director. Sam resumed full time CEO activities in October of 2010.
    Mr Anthony Barry Hall Executive DirectorTechnology Director Jan 1983
    Mr Hall has been principal architect and developer of the core software systems.
    Mr Peter Terence Kempen Non-Executive ChairmanNon-Executive Director Mar 2008
    Mr Kempen is Chairman of Australasian Leukemia and Lymphoma Group. He is also a Trustee of the Barr Family Foundation and a member of the Board of St Hilda's College Ltd, University of Melbourne. Peter has previously been Chairman of Patties Food Limited, Chairman of Danks Holdings Limited, Chairman of Ivanhoe Grammar School and Managing Partner of Ernst and Young Corporate Finance Australia. Peter was appointed a Member in the General Division of the Order of Australia (AM) in the 2018 Queen's Birthday Honours.
    Ms Alice Joan Morrice Williams Non-Executive Director Sep 2021
    Ms Williams is also a non-executive director of Vocus Group, Djerriwarrh Investments, Australian Submarine Corporation (ASC Pty Ltd) and Mercer Investments Australia Ltd. She is chair of the Audit and Risk Committee of Djerriwarrh Investments, ASC and Vocus Group and is a member of the Audit and Risk Committee and Due Diligence Committee of Mercer Investments (Australia) Ltd. Alice holds other board positions with Tobacco Free Portfolios and is on the Advisory Council of the Florey Institute of Neuroscience Novell Project. Previous board roles include Director and Chair of the Audit Committee of Cooper Energy, Chair of Nomination, Remuneration and Human Resources Committee and Non-Executive Director of Equity Trustees Ltd, and Non-Executive member of the Foreign Investment Review Board. She is Chair of Risk committee and also serves on the People and Culture committee.
    Ms Deena Robyn Shiff Non-Executive Director Aug 2020
    Ms Shiff is also Chair of the Supervisory Board of Marley Spoon AG and is an Independent Member of the board of the Global Alliance for Vaccines and Immunisation, the multi-lateral global health fund based in Geneva. Deena is also on the board of Opera Australia. Previous board roles include Chairman of the global board of BAI Communications, Non-Executive Director of Appen, EOS Holdings and Director of the Citadel Group, Vice Chairman of the Government's Export Credit Agency EFIC, as well as board roles in several venture capital backed growth stage ICT companies. She is Chair of the People and Culture committee and serves on the Risk committee.
    Mr Anthony James Glenning Non-Executive Director May 2016
    Mr Glenning is the fund manager of Skalata Ventures, investing in early-stage companies to help them scale and grow into sustainable businesses. He is a Director of Austco Healthcare since September 2018, an international provider of healthcare communication and clinical workflow management solutions. Anthony is also a Director of Iress since October 2022, a technology company providing software to the financial services industry. Anthony has previously been Chairman of Cyrise Pty Ltd, an accelerator for early-stage cyber security start-ups and Investment Director of Starfish Ventures and was the founder and previously the CEO of Tonic Systems and a founding Non-Executive Director of Cameron Systems. He also serves on the People and Culture committee and Risk committee.
    Dr Leigh Bernard Farrell Non-Executive Director Sep 2017
    Dr Farrell is the Head of Health Security Systems Australia, a Division of DMTC, Managing Director of AdNED Pty, non-executive director of both Ena Respiratory Pty and Axelia Oncology Pty, a member of the Walter and Eliza Hall Institute of Medical Research Board Commercialisation Committee, a member of the Independent Advisory Council of Medicines Australia, a member of the Scientific and Industry Advisory Committee of the Australian Research Council Centre for Cryo-electron Microscopy of Membrane Proteins, Chair of the Scientific Advisory Board of Island Pharmaceuticals Ltd and is a member of the National Measurement Institute Mask Testing Forum. Leigh was previously Senior Vice President, Commercial of Certara USA, Inc. where he was responsible for Asia Pacific Commercial. Prior to this, he was Chairman and COO of d3 Medicine LLC, which was acquired by Certara USA, Inc. She also serves on the People and Culture committee and Risk committee.
    Ms Danny English Company Secretary Mar 2023
    Clayton Hatch Chief Financial Officer
    Nick Peace Chief Strategy Officer
    Danny English Company Secretary
    Danny Tauber General Manager Australia
    Malte Westerhoff General Manager Europe and Global Chief Technology Officer
    Brad Levin General Manager North America and Global Head of Marketing
    Teresa Gschwind Global Head of Customer Service
    Sean Lambright Global Head of Sales
    Sharni Redenbach People and Culture Director

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    Dr S Hupert (multiple shareholdings) 26,137,660 25.03%
    Mr A Hall (multiple shareholdings) 26,109,000 25.00%
    HSBC Custody Nominees (Australia) Limited 15,568,938 14.91%
    J P Morgan Nominees Australia Limited 7,320,773 7.01%
    Citicorp Nominees Pty Ltd 6,911,271 6.62%
    National Nominees Limited 1,951,517 1.87%
    BNP Paribas Noms Pty Ltd 1,247,848 1.19%
    Mr Peter Terence Kempen and Mrs Elaine Margaret Kempen (multiple shareholdings) 629,082 0.60%
    Citicorp Nominees (Colonial First State) 605,943 0.58%
    Mr Bram Vander Jagt and Mrs Maaike Vander Jagt 480,000 0.46%
    Grain Exporters (Australia) Pty Ltd 479,000 0.46%
    Mr Michael Wu 429,244 0.41%
    Mr Danny Tauber 290,876 0.28%
    Mr Stephen Geoffrey Wilson and Ms Denise Adele Prandi 285,037 0.27%
    Mr Colin Gregory Organ 271,000 0.26%
    Mr John Charles Plummer 250,000 0.24%
    Mr Kenneth John Vander Jagt and Mrs Tanya Vander Jagt 208,159 0.20%
    Mr Roderick Lyle 190,000 0.18%
    Mr Sean Michael Lambright 179,039 0.17%
    Mr Evan Philip Clucas and Ms Leanne Jane Weston 158,980 0.15%